Corium International, Inc. (NASDAQ:CORI) has been given a $10.00 price target by equities researchers at Jefferies Group LLC in a research report issued on Sunday, October 29th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective indicates a potential downside of 12.51% from the company’s previous close.
A number of other equities analysts also recently weighed in on CORI. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub downgraded Corium International from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday, October 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $12.00 price objective on shares of Corium International in a report on Wednesday, September 27th. Finally, HC Wainwright began coverage on Corium International in a report on Tuesday, September 26th. They issued a “buy” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $13.00.
Shares of Corium International (NASDAQ CORI) traded up $0.74 on Friday, hitting $11.43. The stock had a trading volume of 742,809 shares, compared to its average volume of 182,489. Corium International has a one year low of $2.67 and a one year high of $11.65. The company has a debt-to-equity ratio of 1.89, a quick ratio of 6.80 and a current ratio of 7.04.
TRADEMARK VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/corium-international-inc-cori-given-a-10-00-price-target-at-jefferies-group-llc/1743088.html.
In other news, insider Parminder Singh sold 30,415 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $7.59, for a total value of $230,849.85. Following the completion of the sale, the insider now directly owns 30,762 shares in the company, valued at $233,483.58. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 218,100 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $11.01, for a total value of $2,401,281.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 398,515 shares of company stock valued at $4,289,631. 46.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in CORI. Bank of New York Mellon Corp increased its holdings in Corium International by 118.1% in the 1st quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 13,683 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Corium International in the second quarter valued at about $158,000. California State Teachers Retirement System acquired a new stake in shares of Corium International in the second quarter valued at about $263,000. Teachers Advisors LLC acquired a new stake in shares of Corium International in the second quarter valued at about $272,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Corium International in the second quarter valued at about $411,000. 90.25% of the stock is currently owned by institutional investors and hedge funds.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with our FREE daily email newsletter.